• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Monday 12/10/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Louisiana State University

  • 10:42 AM

    The LSU Agricultural Center has one of the only two licenses granted by the State of Louisiana to cultivate, distribute and sell medical cannabis. In addition, GB Sciences will have first rights to commercialize any inventions or discoveries of the research center. PR Newswire LAS VEGAS, June 26, 2017, GBLX, LAS VEGAS, June 26, 2017 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) secures bid to Louisiana State University (LSU) and receives authorization from the LSU Board of Supervisors to proceed with

    Read more
  • 2:40 PM

    Mar 19, 2015 (ACCESSWIRE via COMTEX) — NEW YORK, NY / ACCESSWIRE / March 19, 2015 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer , David Mazzo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. In his first blog as CEO, Mr. Mazzo writes of his excitement regarding NeoStem’s “prospects to

    Read more
  • 2:02 PM

    Results Support Previous Observation of Dose-Dependent Signals Across Multiple EndpointsNEW YORK, March 16, Mar 16, 2015 (GLOBE NEWSWIRE via COMTEX) — NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the presentation of updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at ACC.15, the American College of Cardiology’s 64th Annual Scientific Session and Expo, in San Diego, California. The one-year

    Read more
  • 2:42 PM

    NEW YORK, March 12, Mar 12, 2015 (GLOBE NEWSWIRE via COMTEX) — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today that the Company’s management will present at the BioCentury Future Leaders in the Biotech Industry Conference on March 20 and at the Alliance for Regenerative Medicine Regen Med Investor Day on March 25. BioCentury 22 Annual Future Leaders in the Biotech Industry — Date and Time: Friday, March 20,

    Read more
  • 3:14 PM

    NEW YORK, March 5, Mar 05, 2015 (GLOBE NEWSWIRE via COMTEX) — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the latest available information from continued follow-up for its PreSERVE study will be presented at ACC.15, the American College of Cardiology’s 64 Annual Scientific Session and Expo, in San Diego, California. On Sunday, March 15, Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator

    Read more
  • 9:57 PM

    NEW YORK, March 2, Mar 02, 2015 (GLOBE NEWSWIRE via COMTEX) — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a biopharmaceutical company developing novel, cell-based personalized medicine therapies, announced today 2014 year end results and provided an update on its business. “We are pleased with our company’s achievements in 2014 and look forward to reporting on our progress advancing the programs in our diversified and balanced pipeline,” said Dr. David J. Mazzo, Chief Executive Officer of NeoStem. “Our near-term focus

    Read more
Public Wire Banner